Perspective Therapeutics Files 8-K: Board, Officer, and Compensation Updates
Ticker: CATX · Form: 8-K · Filed: Sep 3, 2025 · CIK: 728387
Sentiment: neutral
Topics: corporate-governance, officer-changes, compensation
TL;DR
Perspective Therapeutics 8-K: Board/officer changes & comp details filed 9/3/25.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting changes in its board of directors and officers, along with details on compensatory arrangements. The filing also includes information on Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Isoray, Inc., is incorporated in Delaware and based in Seattle, WA.
Why It Matters
This filing signals potential shifts in company leadership and executive compensation, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting standard corporate governance and disclosure items.
Key Numbers
- 001-33407 — SEC File Number (Identifies the company's filing history with the SEC.)
- 411458152 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Isoray, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Seattle, WA (location) — Business address
FAQ
What specific changes were made to the board of directors or officers?
The filing indicates updates regarding the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in this excerpt.
What is the nature of the compensatory arrangements disclosed?
The filing mentions compensatory arrangements of certain officers, but the specific details of these arrangements are not elaborated in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 2, 2025.
What is the company's former name?
The company was formerly known as Isoray, Inc., with previous name changes from IsoRay, Inc. and CENTURY PARK PICTURES CORP.
Where is Perspective Therapeutics, Inc. headquartered?
Perspective Therapeutics, Inc. is located at 2401 Elliott Avenue, Suite 320, Seattle, WA 98121.
Filing Stats: 831 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-09-03 07:04:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $60,000 — provides for an annual cash retainer of $60,000 for her services as a director and an i
- $450,000 — fair value of such grant may not exceed $450,000), which will vest in 36 equal monthly i
Filing Documents
- catx-20250902.htm (8-K) — 50KB
- catx-ex99_1.htm (EX-99.1) — 21KB
- img236230851_0.jpg (GRAPHIC) — 57KB
- 0000728387-25-000010.txt ( ) — 261KB
- catx-20250902.xsd (EX-101.SCH) — 26KB
- catx-20250902_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 3, 2025, the Company issued a press release announcing Ms. Martinez-Davis's appointment to the Board as described in Item 5.02 of this Form 8-K and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 3, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: September 3, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer